ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2023
[Current Treatment Status and Prospect of Surgery and Thermal Ablation for Pulmonary Oligometastases in Non-small Cell Lung Cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- [Research Progress and Challenges of Oligometastasis in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- CBX8 Promotes Epithelial-mesenchymal Transition, Migration, and Invasion of Lung Cancer through Wnt/β-catenin Signaling Pathway.Current protein & peptide science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligometastasis can be regarded as a transition state between early metastasis and extensive metastasis (limited tumor load, unique tumor biological behavior). Due to the relatively limited number of metastatic foci and the number of affected organs, there is a potential chance of cure after active systemic and local treatment. With the rapid development of molecular targeted drug therapy and immunotherapy, local therapy for oligometastatic non-small cell lung cancer (NSCLC), including oligorecurrence and oligoprogression, has received increasing attention. In this paper, the relevant research, efficacy, influencing factors, safety and indications of local therapy such as surgery and thermal ablation were discussed. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.